Key result
Post-MI HbA1c >6.0% in nondiabetic patients is linked to ~277% higher MACE risk versus ≤5.6%.
Why the study?
Does elevated HbA1c predict major adverse cardiac events in nondiabetic patients after acute myocardial infarction?
Observational (n=267)
Yes
Does elevated HbA1c predict major adverse cardiac events in nondiabetic patients after acute myocardial infarction?
Odds Ratio: 3.769 (95% CI 1.3–10.86)
In nondiabetic patients presenting with AMI, an HbA1c level >6.0% is an independent predictor of major adverse cardiac events.
May support closer post-MI surveillance in nondiabetics with HbA1c >6%; leaves open whether targeted intervention improves outcomes.
The effect of glycemic control on the prognosis of nondiabetic patients after acute myocardial infarction (AMI) remains uncertain. We investigated whether glycated hemoglobin (HbA1c) is associated with adverse outcomes after AMI in nondiabetic patients. In this observational study, we enrolled nondiabetic patients with AMI in the emergency department of 2 medical centers from January 2011 to September 2014. All patients received primary percutaneous coronary intervention and were divided into 4 groups according to the interquartile range of average HbA1c level (Group I, ≤5.6%; Group II, 5.6%-5.8%; Group III, 5.8%-6.0%; and Group IV, >6.0%). Multivariate logistic analysis was performed to estimate the correlation of HbA1c with major adverse cardiac events (MACEs) after AMI. In total, 267 eligible patients were enrolled; 48 patients (18%) developed MACEs within a median follow-up of 178 days. Univariate analysis showed HbA1c > 6.0%, with a higher risk of MACEs in Group IV than in Group I (odds ratio [OR]: 2.733; 95% confidence interval [CI]: 1.123-6.651 vs OR: 1.511; 95% CI: 0.595-3.835). Multivariate analysis revealed an approximately 3.8 times higher risk of MACEs in Group IV than in Group I (OR: 3.769; 95% CI: 1.30-10.86). The HbA1 level is a significant predictor of MACEs after AMI in nondiabetic patients.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2017) conducted an observational in acute myocardial infarction (n=267). HbA1c > 6.0% vs. HbA1c ≤ 5.6% was evaluated on major adverse cardiac events (MACEs) (OR 3.769, 95% CI 1.30-10.86). An HbA1c level >6.0% in nondiabetic patients after acute myocardial infarction was associated with a higher risk of major adverse cardiac events compared to ≤5.6% (OR 3.769; 95% CI 1.30-10.86).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: